|
1
|
No authors listed. The world health
organization classification of malignant lymphomas in japan:
Incidence of recently recognized entities. Lymphoma Study Group of
Japanese Pathologist. Pathol Int. 50:696–702. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Flowers CR, Sinha R and Vose JM: Improving
outcomes for patients with diffuse large B-cell lymphoma. CA Cancer
J Clin. 60:393–408. 2010.PubMed/NCBI
|
|
3
|
Feugier P, Van Hoof A, Sebban C,
Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E,
Tilly H, Morschhauser F, et al: Long-term results of the R-CHOP
study in the treatment of elderly patients with diffuse large
B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de
l'Adulte. J Clin Oncol. 23:4117–4126. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoshikawa T, Hara T, Tsurumi H, Goto N,
Hoshi M, Kitagawa J, Kanemura N, Kasahara S, Ito H, Takemura M, et
al: Serum concentration of L-kynurenine predicts the clinical
outcome of patients with diffuse large B-cell lymphoma treated with
R-CHOP. Eur J Haematol. 84:304–309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ninomiya S, Hara T, Tsurumi H, Goto N,
Saito K, Seishima M, Takami T and Moriwaki H: Indoleamine
2,3-dioxygenase expression and serum kynurenine concentrations in
patients with diffuse large B-cell lymphoma. Leuk Lymphoma.
53:1143–1145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Corm S, Berthon C, Imbenotte M, Biggio V,
Lhermitte M, Dupont C, Briche I and Quesnel B: Indoleamine
2,3-dioxygenase activity of acute myeloid leukemia cells can be
measured from patients' sera by HPLC and is inducible by IFN-gamma.
Leuk Res. 33:490–494. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Masaki A, Ishida T, Maeda Y, Suzuki S, Ito
A, Takino H, Ogura H, Totani H, Yoshida T, Kinoshita S, et al:
Prognostic significance of tryptophan catabolism in adult T-cell
leukemia/lymphoma. Clin Cancer Res. 21:2830–2839. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moretti S, Menicali E, Voce P, Morelli S,
Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C,
Alunno A, et al: Indoleamine 2,3-dioxygenase 1 (IDO1) is
up-regulated in thyroid carcinoma and drives the development of an
immunosuppressant tumor microenvironment. J Clin Endocrinol Metab.
99:E832–E840. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoshi M, Ito H, Fujigaki H, Takemura M,
Takahashi T, Tomita E, Ohyama M, Tanaka R, Saito K and Seishima M:
Indoleamine 2,3-dioxygenase is highly expressed in human adult
T-cell leukemia/lymphoma and chemotherapy changes tryptophan
catabolism in serum and reduced activity. Leuk Res. 33:39–45. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Munn DH, Shafizadeh E, Attwood JT,
Bondarev I, Pashine A and Mellor AL: Inhibition of T cell
proliferation by macrophage tryptophan catabolism. J Exp Med.
189:1363–1372. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fallarino F, Grohmann U, Vacca C, Orabona
C, Spreca A, Fioretti MC and Puccetti P: T cell apoptosis by
kynurenines. Adv Exp Med Biol. 527:183–190. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mezrich JD, Fechner JH, Zhang X, Johnson
BP, Burlingham WJ and Bradfield CA: An interaction between
kynurenine and the aryl hydrocarbon receptor can generate
regulatory T cells. J Immunol. 185:3190–3198. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kolodziej LR, Paleolog EM and Williams RO:
Kynurenine metabolism in health and disease. Amino Acids.
41:1173–1183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiu YH, Lei HJ, Huang KC, Chiang YL and
Lin CS: Overexpression of kynurenine 3-monooxygenase correlates
with cancer malignancy and predicts poor prognosis in canine
mammary gland tumors. J Oncol. 2019:62017642019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
De Castro FT, Brown RR and Price JM: The
intermediary metabolism of tryptophan by cat and rat tissue
preparations. J Biol Chem. 228:777–784. 1957. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heyes MP, Chen CY, Major EO and Saito K:
Different kynurenine pathway enzymes limit quinolinic acid
formation by various human cell types. Biochem J. 326:351–356.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thevandavakkam MA, Schwarcz R, Muchowski
PJ and Giorgini F: Targeting kynurenine 3-monooxygenase (KMO):
Implications for therapy in Huntington's disease. CNS Neurol Disord
Drug Targets. 9:791–800. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zwilling D, Huang SY, Sathyasaikumar KV,
Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J,
Andrews-Zwilling Y, Hsieh EW, et al: Kynurenine 3-monooxygenase
inhibition in blood ameliorates neurodegeneration. Cell.
145:863–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kubo H, Hoshi M, Mouri A, Tashita C,
Yamamoto Y, Nabeshima T and Saito K: Absence of kynurenine
3-monooxygenase reduces mortality of acute viral myocarditis in
mice. Immunol Lett. 181:94–100. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mole DJ, Webster SP, Uings I, Zheng X,
Binnie M, Wilson K, Hutchinson JP, Mirguet O, Walker A, Beaufils B,
et al: Kynurenine-3-monooxygenase inhibition prevents multiple
organ failure in rodent models of acute pancreatitis. Nat Med.
22:202–209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Merchen TD, Fang X, Lassiter R, Ho
CS, Jajosky R, Kleven D, Thompson T, Mohamed E, Yu M, et al:
Regulation of indoleamine 2,3 dioxygenase and its role in a porcine
model of acute kidney allograft rejection. J Investig Med.
66:1109–1117. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Terness P, Bauer TM, Röse L, Dufter C,
Watzlik A, Simon H and Opelz G: Inhibition of allogeneic T cell
proliferation by indoleamine 2,3-dioxygenase-expressing dendritic
cells: Mediation of suppression by tryptophan metabolites. J Exp
Med. 196:447–457. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hoshi M, Kubo H, Ando T, Tashita C,
Nakamoto K, Yamamoto Y, Tezuka H and Saito K: 3-Hydroxykynurenine
regulates lipopolysaccharide-stimulated IL-6 production and
protects against endotoxic shock in mice. Immunohorizons.
5:523–534. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sabattini E, Bacci F, Sagramoso C and
Pileri SA: WHO classification of tumours of haematopoietic and
lymphoid tissues in 2008: An overview. Pathologica. 102:83–87.
2010.PubMed/NCBI
|
|
25
|
Miller AA and Salewski E: Prospects for
pirarubicin. Med Pediatr Oncol. 22:261–268. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takagi T and Oguro M:
(2″-R)-4′-o-tetrahydropyranyladriamycin, a new anthracycline
derivative; its effectiveness in lymphoid malignancies. Cancer
Chemother Pharmacol. 20:151–154. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsurumi H, Yamada T, Sawada M, Kasahara S,
Kanemura N, Kojima Y, Fukuno K, Hara T, Saio M, Takahashi T, et al:
Biweekly CHOP or THP-COP regimens in the treatment of newly
diagnosed aggressive non-Hodgkin's lymphoma. A comparison of
doxorubicin and pirarubicin: A randomized phase II study. J Cancer
Res Clin Oncol. 130:107–113. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsurumi H, Hara T, Goto N, Kanemura N,
Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M, Takami T, et
al: A phase II study of a THP-COP regimen for the treatment of
elderly patients aged 70 years or older with diffuse large B-cell
lymphoma. Hematol Oncol. 25:107–114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
International Non-Hodgkin's Lymphoma
Prognostic Factors Project, . A predictive model for aggressive
non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sehn LH, Berry B, Chhanabhai M, Fitzgerald
C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J,
et al: The revised International Prognostic Index (R-IPI) is a
better predictor of outcome than the standard IPI for patients with
diffuse large B-cell lymphoma treated with R-CHOP. Blood.
109:1857–1861. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saito K, Quearry BJ, Saito M, Nowak TS Jr,
Markey SP and Heyes MP: Kynurenine 3-hydroxylase in brain: Species
activity differences and effect of gerbil cerebral ischemia. Arch
Biochem Biophys. 307:104–109. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Skouras C, Zheng X, Binnie M, Homer NZ,
Murray TB, Robertson D, Briody L, Paterson F, Spence H, Derr L, et
al: Increased levels of 3-hydroxykynurenine parallel disease
severity in human acute pancreatitis. Sci Rep. 6:339512016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hajsl M, Hlavackova A, Broulikova K,
Sramek M, Maly M, Dyr JE and Suttnar J: Tryptophan metabolism,
inflammation, and oxidative stress in patients with neurovascular
disease. Metabolites. 10:2082020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carbone PP, Kaplan HS, Musshoff K,
Smithers DW and Tubiana M: Report of the committee on Hodgkin's
disease staging classification. Cancer Res. 31:1860–1861.
1971.PubMed/NCBI
|
|
35
|
Ikezoe T, Miyagi T, Kubota T, Taguchi T,
Ohtsuki Y, Miyake K, Inokuchi K, Nomura T, Koeffler HP and Miyoshi
I: Inactivation of the DCC tumor suppressor gene in a B-cell
lymphoma cell line with the alteration of chromosome 18. Am J
Hematol. 50:124–132. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Taira T, Nagasaki A, Tomoyose T, Miyagi J,
Kakazu N, Makino S, Shinjyo T, Taira N, Masuda M and Takasu N:
Establishment of a human herpes virus-8-negative malignant effusion
lymphoma cell line (STR-428) carrying concurrent translocations of
BCL2 and c-MYC genes. Leuk Res. 31:1285–1292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hoshi M, Saito K, Hara A, Taguchi A,
Ohtaki H, Tanaka R, Fujigaki H, Osawa Y, Takemura M, Matsunami H,
et al: The absence of IDO upregulates type I IFN production,
resulting in suppression of viral replication in the
retrovirus-infected mouse. J Immunol. 185:3305–3312. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Garten A, Schuster S, Penke M, Gorski T,
de Giorgis T and Kiess W: Physiological and pathophysiological
roles of NAMPT and NAD metabolism. Nat Rev Endocrinol. 11:535–546.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kaper T, Looger LL, Takanaga H, Platten M,
Steinman L and Frommer WB: Nanosensor detection of an
immunoregulatory tryptophan influx/kynurenine efflux cycle. PLoS
Biol. 5:e2572007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ninomiya S, Hara T, Tsurumi H, Hoshi M,
Kanemura N, Goto N, Kasahara S, Shimizu M, Ito H, Saito K, et al:
Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in
patients with diffuse large B-cell lymphoma treated with R-CHOP.
Ann Hematol. 90:409–416. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vazquez S, Garner B, Sheil MM and Truscott
RJ: Characterisation of the major autoxidation products of
3-hydroxykynurenine under physiological conditions. Free Radic Res.
32:11–23. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chiarugi A, Dölle C, Felici R and Ziegler
M: The NAD metabolome - a key determinant of cancer cell biology.
Nat Rev Cancer. 12:741–752. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chiche J, Pommier S, Beneteau M, Mondragón
L, Meynet O, Zunino B, Mouchotte A, Verhoeyen E, Guyot M, Pagès G,
et al: GAPDH enhances the aggressiveness and the vascularization of
non-Hodgkin's B lymphomas via NF-κB-dependent induction of HIF-1α.
Leukemia. 29:1163–1176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chowdhury S, Sripathy S, Webster A, Park
A, Lao U, Hsu JH, Loe T, Bedalov A and Simon JA: Discovery of
selective SIRT2 inhibitors as therapeutic agents in B-cell lymphoma
and other malignancies. Molecules. 25:4552020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Braidy N, Grant R, Brew BJ, Adams S,
Jayasena T and Guillemin GJ: Effects of kynurenine pathway
metabolites on intracellular NAD synthesis and cell death in human
primary astrocytes and neurons. Int J Tryptophan Res. 2:61–69.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pittelli M, Formentini L, Faraco G,
Lapucci A, Rapizzi E, Cialdai F, Romano G, Moneti G, Moroni F and
Chiarugi A: Inhibition of nicotinamide phosphoribosyltransferase:
Cellular bioenergetics reveals a mitochondrial insensitive NAD
pool. J Biol Chem. 285:34106–34114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kristeleit R, Davidenko I, Shirinkin V,
El-Khouly F, Bondarenko I, Goodheart MJ, Gorbunova V, Penning CA,
Shi JG, Liu X, et al: A randomised, open-label, phase 2 study of
the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as
therapy for biochemically recurrent (CA-125 relapse)-only
epithelial ovarian cancer, primary peritoneal carcinoma, or
fallopian tube cancer. Gynecol Oncol. 146:484–490. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Beatty GL, O'Dwyer PJ, Clark J, Shi JG,
Bowman KJ, Scherle PA, Newton RC, Schaub R, Maleski J, Leopold L,
et al: First-in-human phase I study of the oral inhibitor of
indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients
with advanced solid malignancies. Clin Cancer Res. 23:3269–3276.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al:
Distinct types of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
|
